Mark W Russo

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
    Liver Transpl 11:1235-41. 2005
  2. ncbi Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C
    Mark W Russo
    University of North Carolina, Division of Gastroenterology and Hepatology, Bioinformatics Bldg Rm 1104, 130 Mason Farm Road, Chapel Hill, NC 27599 7080, USA
    Nephrol Dial Transplant 21:437-43. 2006
  3. ncbi Liver transplantation for acute liver failure from drug induced liver injury in the United States
    Mark W Russo
    Division of Gastroenterology and Hepatology, Department of Medicine and Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:1018-23. 2004
  4. ncbi Interpretation of liver chemistries in adult donors after living donor liver transplantation
    Mark W Russo
    Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, USA
    J Clin Gastroenterol 38:810-4. 2004
  5. ncbi Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C
    Mark W Russo
    Department of Medicine and the Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:1133-8. 2004
  6. ncbi Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States
    Mark W Russo
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:340-6. 2004
  7. ncbi Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:427-31. 2004
  8. ncbi How to use statins in patients with chronic liver disease
    Mark W Russo
    Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA
    Cleve Clin J Med 71:58-62. 2004
  9. ncbi Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors
    Paul J Gaglio
    Department of Medicine, Columbia University College of Physicians and Surgeons, Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, NY 10032, USA
    Liver Transpl 9:1028-35. 2003
  10. ncbi Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT
    Ira M Jacobson
    Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Am J Gastroenterol 99:1700-5. 2004

Collaborators

Detail Information

Publications45

  1. ncbi Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
    Liver Transpl 11:1235-41. 2005
    ..004). In conclusion, hepatic stellate cell activation early after liver transplantation complements traditional testing for identifying liver transplant recipients with hepatitis C at greatest risk for developing advanced fibrosis...
  2. ncbi Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C
    Mark W Russo
    University of North Carolina, Division of Gastroenterology and Hepatology, Bioinformatics Bldg Rm 1104, 130 Mason Farm Road, Chapel Hill, NC 27599 7080, USA
    Nephrol Dial Transplant 21:437-43. 2006
    ..Chronic hepatitis C infection is prevalent among haemodialysis patients. The goal of our study was to determine the efficacy and safety of pegylated interferon alpha-2b in haemodialysis patients with chronic hepatitis C...
  3. ncbi Liver transplantation for acute liver failure from drug induced liver injury in the United States
    Mark W Russo
    Division of Gastroenterology and Hepatology, Department of Medicine and Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:1018-23. 2004
    ..The increased frequency of African-American women undergoing liver transplantation for non-APAP drug induced liver injury warrants further study...
  4. ncbi Interpretation of liver chemistries in adult donors after living donor liver transplantation
    Mark W Russo
    Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, USA
    J Clin Gastroenterol 38:810-4. 2004
    ..The safety of donors is paramount in adult living donor liver transplantation. Our goal is to compare the pattern of recovery of hepatic synthetic function and aminotransferases in healthy adult donors with and without complications...
  5. ncbi Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C
    Mark W Russo
    Department of Medicine and the Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:1133-8. 2004
    ..Older donor age is associated with lower short-term graft survival in recipients with hepatitis C, but not in recipients with cholestatic or alcoholic liver disease...
  6. ncbi Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States
    Mark W Russo
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:340-6. 2004
    ..68. Short-term patient and graft survival are similar between living donor and deceased donor liver transplant recipients with hepatitis C suggesting that recurrent hepatitis C does not seem to affect short-term outcomes...
  7. ncbi Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:427-31. 2004
    ..In the era of living donor liver transplantation, estimates of patient survival should incorporate waiting time mortality...
  8. ncbi How to use statins in patients with chronic liver disease
    Mark W Russo
    Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA
    Cleve Clin J Med 71:58-62. 2004
    ..However, patients with acute liver disease (acute viral hepatitis, alcoholic hepatitis) should not take statins until they have recovered...
  9. ncbi Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors
    Paul J Gaglio
    Department of Medicine, Columbia University College of Physicians and Surgeons, Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, NY 10032, USA
    Liver Transpl 9:1028-35. 2003
    ..Thus, in this patient population, the timing and incidence of HCV recurrence were not different when comparing CAD versus LDLT, but the incidence of cholestatic hepatitis was significantly greater in patients with HCV who underwent LDLT...
  10. ncbi Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT
    Ira M Jacobson
    Department of Gastroenterology and Hepatology, Weill Medical School of Cornell University, 450 East 69th Street, New York, NY 10021, USA
    Am J Gastroenterol 99:1700-5. 2004
    ..Patients with CHC should not be excluded from treatment on the basis of ALT alone. Combination therapy with pegylated interferon and ribavirin should be evaluated in these patients...
  11. ncbi A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C
    Ira M Jacobson
    Center for the Study of Hepatitis C and Division of Gastroenterology and Hepatology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Am J Gastroenterol 100:2453-62. 2005
    ..There was no significant effect of dosing regimen...
  12. ncbi Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria
    Tarun K Narang
    Department of Medicine, Carolinas Medical Center, Charlotte, NC 28203, USA
    Liver Transpl 16:1228-35. 2010
    ..We propose that studies on PLTCHC use the consensus criteria for diagnosis and suggest clinical information that should be provided in future studies with the goal of improving our understanding and management of this deadly disease...
  13. ncbi Management of newly diagnosed hepatitis C virus infection
    Mark W Russo
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, USA
    Cleve Clin J Med 70:S14-20. 2003
    ..Careful and timely management of side effects, which are experienced by all patients, can improve adherence to antiviral therapy and further improve response rates...
  14. ncbi The burden of gastrointestinal and liver diseases, 2006
    Nicholas J Shaheen
    Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Gastroenterol 101:2128-38. 2006
    ..CONCLUSIONS: Gastrointestinal and liver diseases are significant contributors to the morbidity, mortality, and health-care expenditures of the U.S. population...
  15. ncbi Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery
    Yong Yook Lee
    Department of Research, Carolinas HealthCare System, Charlotte, NC, USA
    J Proteome Res 10:5070-83. 2011
    ..Here we demonstrate an efficient strategy of subcellular tissue proteomics toward molecular target discovery of one of the most complicated human disease, HCC...
  16. ncbi Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality
    Mark W Russo
    Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7080, USA
    Am J Gastroenterol 98:2521-7. 2003
    ..Renal insufficiency, refractory encephalopathy, and hyperbilirubinemia were consistently associated with mortality after TIPS. In individuals with risk factors for mortality, alternative strategies should be recommended...
  17. ncbi Guidelines for stopping therapy in chronic hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, University of North Carolina, CB#7080, Room 1111, Bioinformatics Building, Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr Gastroenterol Rep 6:17-21. 2004
    ..Progress in defining early treatment stopping points has reduced adverse events in patients who are unlikely to respond to therapy...
  18. ncbi Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis
    K Shiva Kumar
    Center for Liver Disease and Transplantation, New York-Presbyterian Hospital, New York 10036, USA
    Gastroenterology 122:2026-31. 2002
    ..This is the first reported patient with primary amyloidosis to undergo sequential liver and stem cell transplantation leading to resolution of the disease and only the second to undergo successful liver transplantation for this disorder...
  19. ncbi Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients
    Robert S Brown
    Center for Liver Disease and Transplantation, New York Presbyterian Hospital, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Liver Transpl 8:278-84. 2002
    ..However, neither score correlated with resource use post-OLT in the strata of critically ill patients...
  20. ncbi Side effects of therapy for chronic hepatitis C
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
    Gastroenterology 124:1711-9. 2003
  21. ncbi Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety
    Mark W Russo
    Division of Digestive Diseases and Nutrition, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Am J Gastroenterol 98:1610-5. 2003
    ..Interferon monotherapy is associated with more adverse events in dialysis patients. The optimal dose and duration of interferon monotherapy and selection criteria of dialysis patients need to be studied further in clinical trials...
  22. ncbi Adult living donor liver transplantation
    Mark W Russo
    Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:458-65. 2004
    ..Further growth of LDLT will depend on defining the optimal recipient and donor characteristics for this procedure as well as broader acceptance and experience in the public and in transplant centers...
  23. ncbi A survey of liver transplantation from living adult donors in the United States
    Robert S Brown
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
    N Engl J Med 348:818-25. 2003
    ..Although the use of grafts from living donors is standard practice in transplantation in children, their use in adults remains controversial...
  24. ncbi Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors
    Dianne Lapointe Rudow
    Center for Liver Disease and Transplantation, New York Presbyterian Hospital, New York, NY, USA
    Liver Transpl 9:254-9. 2003
    ..Further understanding of the cultural differences and motivating factors for why people volunteer for evaluation and subsequently choose to donate may help improve cadaveric and living donor transplant rates...
  25. ncbi Drug-induced liver injury associated with statins
    Mark W Russo
    Department of Medicine, Carolinas Medical Center, Charlotte, North Carolina 28203, USA
    Semin Liver Dis 29:412-22. 2009
    ..Multiple retrospective studies as well as a large prospective randomized controlled trial demonstrate that statins can safely be given to hyperlipidemic patients with compensated chronic liver disease...
  26. ncbi The risk of hepatocellular carcinoma in cirrhotic patients with small liver nodules on MRI
    Tilak U Shah
    Division of Gastroenterology and Hepatology and Center for Gastroenterology Biology and Disease, University of North Carolina, Chapel Hill, NC 27599-7080, USA
    Am J Gastroenterol 101:533-40. 2006
    ..CONCLUSION: The incidence of HCC in patients with small liver nodules is significantly higher compared to patients with cirrhosis without liver nodules. The presence of small liver nodules warrants increased imaging surveillance for HCC...
  27. ncbi Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C
    K Shiva Kumar
    Center for Liver Disease and Transplantation, New York-Presbyterian Hospital, New York, USA
    Am J Gastroenterol 97:2432-40. 2002
    ..Though usually reversible, at least one case has required long-term steroids with inadequate resolution. Though pulmonary toxicity is rare, symptoms which are more than mild or progressive in nature should likely be investigated...
  28. ncbi Accuracy of magnetic resonance imaging for preoperative detection of portal vein thrombosis in liver transplant candidates
    Tilak U Shah
    Department of Gastroenterology and Hepatology and Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
    Liver Transpl 12:1682-8. 2006
    ..In conclusion, in our study group MRI detected PVT in all liver transplant recipients requiring jump grafts at transplantation. The major reason for a false-positive MRI was a diminutive but patent portal vein...
  29. ncbi Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial
    Nicholas J Shaheen
    Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Hepatology 41:588-94. 2005
    ..However, the total ulcer number and patient symptoms were not different between the groups...
  30. ncbi Financial impact of adult living donation
    Mark W Russo
    University of North Carolina, Chapel Hill, NC, USA
    Liver Transpl 9:S12-5. 2003
  31. ncbi Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans
    Alison H Harrill
    Curriculum in Toxicology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Genome Res 19:1507-15. 2009
    ..These studies demonstrate that a diverse mouse population can be used to understand and predict adverse toxicity in heterogeneous human populations through guided resequencing...
  32. ncbi Ethical issues in living donor liver transplantation
    Mark W Russo
    Center for Liver Disease and Transplantation, Columbia Presbyterian Medical Center, 622 West 168th Street, PH 14, New York, NY 10032, USA
    Curr Gastroenterol Rep 5:26-30. 2003
    ..The medical community has an obligation to study carefully the risks and outcomes associated with ALDT so that we can deliver the highest quality of care that is not at the expense of healthy individuals...
  33. ncbi Digestive and liver diseases statistics, 2004
    Mark W Russo
    Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599-7555, USA
    Gastroenterology 126:1448-53. 2004
    ..Following trends in utilization is important for determining allocation of resources for health care and research...
  34. ncbi Endoscopic stent insertion into the gallbladder for symptomatic gallbladder disease in patients with end-stage liver disease
    Jason D Conway
    Department of Medicine: Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, 27599-7080, USA
    Gastrointest Endosc 61:32-6. 2005
    ..CONCLUSIONS: Endoscopic stent placement in the gallbladder is a safe and an effective palliative treatment for patients with symptoms caused by gallbladder disease who are poor surgical candidates...
  35. ncbi Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt
    Mark W Russo
    Weill Medical College of Cornell University, New York, NY, USA
    Liver Transpl 8:271-7. 2002
    ..Individuals with both coagulopathy and renal insufficiency had high mortality. Urgent TIPS placement for uncontrolled variceal bleeding was associated with stenosis...
  36. ncbi Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature
    Evan S Dellon
    University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology, CB 7080, Bioinformatics Bldg, Rm 1140, 130 Mason Farm Rd, Chapel Hill, NC 27599 7080, United States
    World J Gastroenterol 12:4089-92. 2006
    ..This case demonstrates that liver biopsy is essential in diagnosing unusual causes of acute liver failure, and that infiltration of the liver with NK-like T-cell lymphoma/leukemia can cause acute liver failure...
  37. ncbi Liver function tests and statins
    Philippe J Zamor
    Department of Medicine, Center for Liver Diseases and Transplantation, Carolinas Medical Center, Charlotte, North Carolina 28203, USA
    Curr Opin Cardiol 26:338-41. 2011
    ..To discuss recent data on statins in patients with elevated liver tests...
  38. ncbi A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis
    Pradyumna Phatak
    Rochester General Hospital, Rochester, NY, USA
    Hepatology 52:1671-779. 2010
    ..Based on the safety and efficacy results, starting deferasirox at 10 mg/kg/day appears to be most appropriate for further study in this patient population...
  39. ncbi Discovery of putative pancreatic cancer biomarkers using subcellular proteomics
    Kimberly Q McKinney
    Proteomics Laboratory for Clinical and Translational Research, Carolinas HealthCare System, Charlotte, NC, USA
    J Proteomics 74:79-88. 2011
    ..We conclude that subcellular fractionation followed by gel electrophoresis and tandem mass spectrometry is a powerful strategy for identification of differentially expressed proteins in pancreatic cancer...
  40. ncbi Reporting outcomes on living donor liver transplant
    Mark W Russo
    Liver Transpl 11:244; author reply 245. 2005
  41. ncbi Is severe recurrent hepatitis C more common after adult living donor liver transplantation?
    Mark W Russo
    Hepatology 40:524-6. 2004
  42. ncbi Are patients with elevated liver tests at increased risk of drug-induced liver injury?
    Mark W Russo
    Gastroenterology 126:1477-80. 2004
  43. ncbi Evaluating the potential living liver donor
    Mark W Russo
    Liver Transpl 10:1097-8. 2004
  44. ncbi MELD and serum sodium
    Mark W Russo
    Hepatology 41:1198-9; author reply 1199; discussion 1199. 2005
  45. ncbi A double-blind comparison of intravenous ondansetron and placebo for preventing postoperative emesis in 1- to 24-month-old pediatric patients after surgery under general anesthesia
    Samia N Khalil
    Department of Anesthesiology, University of Texas Health Science Center, Houston 77030, USA
    Anesth Analg 101:356-61, table of contents. 2005
    ..1 mg/kg) in the prevention of postoperative emesis in 1- to 24-mo-old pediatric patients undergoing elective surgery under general anesthesia...